Overview

Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids

Status:
Completed

Trial end date:
2007-10-01

Target enrollment:

Participant gender:

Summary

In patients with at least moderate persistent allergic asthma controlled with inhaled steroids, omalizumab (administered per US product label), when compared to placebo, will provide the participants with significantly improved tolerability of specific allergen immunotherapy (allergy shots) administered per a cluster schedule(rapid build up method).

Phase:

Phase 4

Details

Lead Sponsor:

University of Mississippi Medical Center

Collaborator:

Novartis

Treatments:

Omalizumab